GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy
Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...
18 Elo 48min
FAQ: Counseling Patients on Overt Hepatic Encephalopathy
Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...
11 Elo 4min
Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...
23 Heinä 7min
Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC
Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...
30 Kesä 17min
Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease
Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...
9 Kesä 12min
FAQ: QUASAR Long Term Extension Interim Analysis
Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...
2 Kesä 4min
Medication Review: Guselkumab IV vs SC Formulation
Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...
28 Touko 3min
